VIVES is a multi-sector fund that invests in projects with a positive societal impact
Spinovit, a UCLouvain spin-off, is developing a method for the quantitative analysis of an oxygen-sensitive blood biomarker to measure endothelial dysfunction and prevent cardiovascular risks.
Cardio...
ATB Therapeutics is pioneering a new era in targeted therapies by developing next-generation Antibody-Drug Conjugates (ADCs) to transform cancer treatment. By combining cutting-edge biotechnology with...
Axinesis is a spin-off of the Université Catholique de Louvain (BE), which has a clear mission: to improve the functional recovery of patients through innovative and accessible technologies dedicated...
Gael Rouvroy, CEO intoPIX:
"VIVES fund has been a great partner in early and mature stages of intoPIX. They recognized the potential of the market and the technology with a primary recognition for...
Pierre Blondeau, CEO Upstreem:
"We have been working since 2017 with VIVES II, which has joined us since the beginning of our adventure. VIVES II team has an in-depth understanding of all aspects of...
Willem de Vos, Prof. at University of Wageningen; Patrice Cani, Prof. at UCLouvain; Jean-Christophe Malrieu, CEO A-Mansia:
"As founders and CEO of A-mansia BioTech we experienced essential support...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to